Dr. Reddy’s Q1FY27 profit after tax drops 69% YoY to ₹4.44 billion; revenue falls 5.6% YoY to ₹80.71 billion

• Dr. Reddy’s posted Q1FY27 revenue of ₹ 80.71 billion, down 5.6% YoY; profit after tax attributable to equity holders fell 69% to ₹ 4.44 billion.
• EBITDA dropped to ₹ 10.09 billion, with margin narrowing to 12.5% from 26.7% a year earlier.
• Gross margin slid 10.4 percentage points to 46.5%, including a ₹ 2.4 billion provision tied to semaglutide API-related inventory and associated costs.
• North America revenue declined 35% YoY to ₹ 22.05 billion, while Emerging Markets climbed 31% to ₹ 18.33 billion.
• Management flagged a transition beyond lenalidomide revenue, while highlighting double-digit underlying base-business growth and continued pipeline buildout in peptides and biosimilars.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.